NEW YORK, Nov. 11, 2014 /PRNewswire/ -- Faruqi &
Faruqi, LLP, a leading national securities law firm, is
investigating potential securities fraud at Aeterna Zentaris
Inc. ("Aeterna" or the "Company") (NASDAQ: AEZS).
The investigation focuses on whether the Company and its
executives violated federal securities laws by making false and
misleading statements and/or failing to disclose material facts
regarding its business and operations.
On November 6, 2014, Aeterna
announced that it had received a Complete Response Letter from the
Food and Drug Administration indicating that the New Drug
Application for the Company's drug Macrilen "cannot be approved in
its present form."
Following this news, the price of Aeterna stock declined by
$0.64 per share, or nearly 50%, to
close on November 6, 2014 at
$0.65 per share.
Request more information now by clicking here:
www.faruqilaw.com/AETERNA. There is no cost or obligation to
you.
Take Action
If you invested in Aeterna stock or options prior to
November 6, 2014 and would like to
discuss your legal rights, visit www.faruqilaw.com/AETERNA. You can
also contact us by calling Richard
Gonnello toll free at 877-247-4292 or at 212-983-9330 or by
sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi,
LLP also encourages anyone with information regarding Aeterna's
conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.
Attorney Advertising. The law firm responsible for this
advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with
respect to any future matter. We welcome the opportunity to
discuss your particular case. All communications will be
treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello,
Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Logo -
http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
SOURCE Faruqi & Faruqi, LLP